Dermatology Summit 2025

Biography

A leader of scientific innovation and a winner of the Emerging Women Founder Award, Cheri co-founded Concerto to reinvent humanity’s relationship with microbes. Cheri led Concerto to raise oversubscribed Seed and Series A investment rounds, fueling the company’s development of transformative microbial treatments and industry partnerships. Cheri has built a strong company culture centered around rigorous science, intent listening, and compassion. She holds a PhD in Chemistry from UC Berkeley (Hertz Fellow) and completed a postdoctoral fellowship at the Broad Institute of MIT and Harvard (NIH Kirschstein Fellow).

Biography

Liav Abraham is a Managing Director in UBS' Global Healthcare group based in NY, where she focuses on advising life sciences companies on a variety of strategic and capital markets transactions, including in the dermatology and aesthetics therapeutic areas. Liav joined UBS in 2023 following the acquisition of Credit Suisse, and prior to her time at Credit Suisse, she was a biopharma equity research analyst at both Citi and Morgan Stanley, where she covered stocks in the pharmaceuticals sector. She holds an MBA from Columbia University.

Biography

Dr. Alvarado is a Vice President in the Research Department at Celldex Therapeutics, where he oversees discovery and translational medicine activities. He joined Celldex in 2016 as a Director of Research, where he contributed to the discovery and preclinical development of several programs, including barzolvolimab (CDX-0159). Previously, he was a Director and Senior Scientist at Kolltan Pharmaceuticals from 2010 to 2016, where he oversaw the discovery, preclinical development, and biomarker discovery for several monoclonal antibodies and antibody-drug conjugates targeting receptor tyrosine kinases (RTKs). Dr. Alvarado did his postdoctoral work at the University of Pennsylvania with Dr. Mark Lemmon, focusing on the structural mechanisms governing activation and inhibition of receptor tyrosine kinases. Dr. Alvarado received his Ph.D. in Molecular, Cellular and Developmental Biology from Indiana University in 2004.

Biography

Dr. Avram is one of the leading medical authorities on cosmetic dermatology in the world. He is the Past-President of the American Society for Dermatologic Surgery, the leading organization in the United States for cosmetic dermatology with 6,400 physician members who elected him to this prestigious position. He has served as the Director of the Massachusetts General Hospital Dermatology Laser & Cosmetic Center for 18 years. He also serves as Faculty Director for Laser and Cosmetic Training in the Department of Dermatology at Harvard Medical School.
Dr. Avram was elected by his peers and served as President of the American Society for Laser Medicine Surgery (ASLMS) in 2017-2018, the leading society in the world for laser and energy-based treatments with 4,400 members at that time. He was the 2015 recipient of the ASLMS Annual Leon Goldman Award for excellence in research, patient care, and education, and he was the 2016 recipient of the ASLMS Annual Ellet Drake Award for innovation in laser surgery.
Dr. Avram has co-authored or edited 7 textbooks that have been translated into 5 languages. He has 90 peer-reviewed publications in journals including the New England Journal of Medicine. He has served as co-investigator for five annual Best Science Awards at ASLMS. Dr. Avram has chaired 31 national meetings and has delivered over 800 invited lectures at national and international meetings on 4 continents. Dr. Avram served as co-chair for an annual laser and energy-based teaching session for the FDA in Silver Spring, Maryland for three years. He also has two U.S. patents.
This year, Dr. Avram was recognized by Newsweek magazine as one of the Top 10 cosmetic dermatologists in America. For 10 consecutive years, Dr. Avram has been selected as one of Boston's Top Dermatologists by Boston Magazine. Dr. Avram is a frequent guest on ABC, NBC, CNN, CBS, FOX and is a regularly quoted medical expert in the New York Times, Wall Street Journal, Washington Post and numerous other media publications.

Biography

Christophe Bourdon joined LEO Pharma A/S as CEO in April 2022. In this role, Bourdon has led the company through a significant transformation, substantially growing its topline, improving profitability, and developing a new innovation model to create more effective and user-friendly medicines that address unmet needs in medical dermatology. During the same time, the company achieved multiple product approvals and launches, including in the U.S., EU, and China.

During his 25 years in the pharmaceutical industry across 3 continents, Bourdon’s focus has been to build strong and diverse teams, while fostering an environment focused on innovation and curiosity with one constant driver in mind: Making a meaningful difference for patients.

Prior to joining LEO Pharma, he served as CEO at Orphazyme A/S. Earlier in his career, Bourdon held a series of leadership roles at Amgen, including Senior Vice President and General Manager for the U.S. Oncology Business, with ten marketed portfolios comprising one of the company’s largest businesses. During his tenure in the US, Bourdon helped launching 3 oncology products, managed to launch 2 biosimilars, and accelerated Amgen’s pipeline focus on new innovative cancer medicine.

Earlier, Bourdon was Vice President and General Manager for Amgen, Germany. He also worked at Alexion as Senior Vice President, EMEAC, leading the commercial development of ultra-orphan therapies across 40 countries.

He earned his MBA from the International Institute for Management Development (IMD), Lausanne, Switzerland, and a BA from the Institut Superieur de Gestion/ISG, Paris, France.

Biography

Following a postdoc in cancer cell biology, Orla returned to Ireland to establish Wyeth's nascent antibody discovery & engineering group; subsequently acquired by Pfizer. In her role at Pfizer, Orla led multi-disciplinary internal antibody discovery teams, in addition to academic collaborations with universities across Ireland & the UK. She has supported pre-clinical programs from conception through development, with many candidates currently progressing through clinical trials. Orla left big pharma for the start-up biotech world in 2020, and is currently global program lead for Alys Pharmaceuticals, focusing on next-generation mast cell targeting. Throughout her 20 year career Orla has published and patented widely in the field of therapeutic antibody engineering.

Biography

Dr. Gil has had a 30+ year career in Pharmaceutical R&D. He is CEO of Pelage Pharmaceuticals, which is conducting clinical trials on a regenerative hair growth treatment. He is also a Venture Partner with Visionary Ventures, an ophthalmology and aesthetics-focused fund. Until 2018, Dr. Gil worked at Allergan. As VP, Research Technologies and Portfolio, he oversaw preclinical to early phase 2 clinical development and directed the Medicinal Chemistry, Biologics and translational pharmacology research groups. His research contributed to development of 5 marketed drugs and he led 8 clinical development projects in the areas of Ophthalmology, Neuroscience and Dermatology. He is an inventor on more than 70 issued US patents and author on 50 peer-reviewed research articles. Dr. Gil has an undergraduate degree in Biology from Harvard University and a PhD in Pharmacology from the University of Pennsylvania.

Biography

Scott Gottlieb, MD, is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. He is currently a senior fellow at the American Enterprise Institute for Public Policy Research and a partner at the venture capital firm New Enterprise Associates.

Under his leadership, the FDA advanced new frameworks for the modern oversight of gene therapies, cell-based medicines, and digital health devices. The agency implemented new reforms to standardize drug reviews and made historic improvements in post-market data collection and the use of real-world evidence. He promoted policies to reduce death and disease from tobacco, improve food safety, and aggressively confront addiction crises. The agency’s prolific advances in new policy distinguished his tenure as FDA Commissioner, along with a record-setting number of approvals for novel drugs, medical devices, and generic medicines.

Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and, before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services. He is the author of the New York Times bestselling book “Uncontrolled Spread: Why Covid-19 Crushed Us and How We Can Defeat the Next Pandemic” and is a regular contributor to CNBC and CBS News’ Face the Nation. Dr. Gottlieb serves on the board of directors of publicly traded companies Pfizer, Inc., Illumina, Inc., and TempusAI.

Dr. Gottlieb is an elected member of the National Academy of Medicine and completed medical school and a residency in internal medicine at the Mount Sinai School of Medicine, where he currently serves on the executive committee of the Mount Sinai Health System’s board of directors and co-chairs the board’s education committee. He graduated from Wesleyan University, where he majored in economics, and currently serves on the university’s board of directors.

Biography

Dr. William Greene’s leadership positions have included founder, biotechnology executive, investor, and clinician. As CEO, he built Iconic Therapeutics through discovery, clinical development and venture financing, leading to a successful sale of the company. He later helmed longevity biotech company Fountain Therapeutics and co-founded digital therapeutics startup Pear Therapeutics.

Dr. Greene spent 12 years at MPM Capital where he was a Managing Director and member of its Investment Committee, responsible for biotechnology and medical technology investments worldwide. He was also founding Chairman and head of the Investment Committee at the Global Health Investment Fund, a groundbreaking impact-oriented venture fund in collaboration with the Gates Foundation, which successfully scaled both investment returns and health impact simultaneously.

Earlier in his career, Dr. Greene was an Assistant Professor of Medicine at University of California at San Francisco (UCSF) and led clinical trials and strategy for a variety of therapeutic areas at Genentech.

Dr. Greene earned his BA from Wesleyan University and his MD from UCSF. He was a Robert Wood Johnson Clinical Scholar at Yale and a Howard Hughes Medical Institute Research Scholar at the US National Institutes of Health (NIH).

Biography

Dr. J. Mark Jackson joins Evommune from his position as a Clinical Professor of Medicine at the University of Louisville. Besides his academic appointment, he also previously served as an advisor to multiple pharmaceutical companies including AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, and held a leadership role in a clinical practice with Forefront Dermatology. He has been involved in clinical research for over 25 years, with a focus on early drug development. Mark has authored over 50 articles in peer reviewed publications as well as chapters in numerous well-known dermatology textbooks. He has lectured nationally and internationally on topics involving lupus, neutrophilic disorders, psoriasis, atopic dermatitis, systemic therapies for dermatologic diseases, drug reactions, advanced dermatologic disorders, and acne. He serves on the editorial review team for JAMA Dermatology, and the Journal of the American Academy of Dermatology, and served as President of the American Acne and Rosacea Society from 2019 to 2021. Mark received his undergraduate degree from Baylor University and his medical degree from Texas A&M College of Medicine.

Biography

Dr. Kim received his MD from the University of Washington, was a HHMI-NIH Scholar, completed residency in dermatology at the University of Pennsylvania where he earned a Master of Translational Research (MTR). His research focuses on mechanisms that underlie skin inflammation and the sensation of itch as a fundamental, broad, model paradigm of neuroimmunology. He has >120 peer-reviewed publications, multiple NIH grants, designed pivotal clinical trials that led to novel FDA-approved treatments, and is an inventor of itch-centered technologies. His research has led to awards and funding from NIH, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology, American Society for Clinical Investigation, American Dermatological Association, and International League of Dermatological Societies. He holds a patent for the use of JAK inhibitors for itch. He is on the SAB for Abrax Japan, Granular Therapeutics, Recens Medical, National Eczema Association, and Cell Reports Medicine.

Biography

After Graduating from the Copenhagen Medical Faculty in 1994, Kim Kjøller, held several positions at Copenhagen University Hospitals in medicine and surgery until joining the Danish Cancer Society, Institute for Epidemiologic Cancer Research in 1996. Joining the Pharmaceutical industry in the medical area in 1999 and has since held positions at Sanofi, Lundbeck, Sanofi Pasteur MSD and lastly LEO Pharma from 2010; from 2015 until 2020 as Executive Vice President R&D, and member of the Global Leadership team. Kim Kjøller has since 2021 served as chairman of the Danish Life Science Cluster, a private-public organization established to foster collaboration, between, academia, business, communities and regions to jointly progress innovation and improve health care delivery in Denmark.
Kim Kjøller is author/Co-Author of 40+ scientific publications, and has given lecturers at Scientific Meetings in Denmark and the Nordics as well as at Pharma Industry Meetings in Europe and the US.

Biography

Alex Laslavic is the Chief Technology Officer at Rubedo Life Sciences, where he has been driving technological innovation since 2018. With 23 years of experience as a computer engineer, Alex has a proven track record of building and leading high-performing engineering teams, designing robust infrastructure, and developing distributed systems.
Prior to Rubedo, Alex honed his skills at industry-leading companies like Facebook and Turner Broadcasting. Today, he uses his computational expertise to advance aging science, therapeutics, and regenerative medicine. Alex excels in building pipelines for large-scale data analysis, paving the way for breakthroughs in cutting-edge life sciences research.

Biography

Uri is an Operating Partner at Khosla Ventures, where he focuses on biotech and life sciences.

Prior to KV, Uri was the founding CEO of Pardes Biosciences (NASDAQ:PRDS), a biotech focused on utilizing reversible-covalent chemistry to develop small molecule oral antivirals for the treatment and prevention of SARS-CoV2 infections. Uri led Pardes from conception through phase 1 and its public listing via SPAC.

Before Pardes Biosciences, Uri was a visiting group partner at Y Combinator where he focused on their biotech portfolio companies. This followed his role as founder and Chief Medical Officer at Assembly Biosciences (NASDQ:ASMB) an antiviral company developing novel therapies for chronic HBV. Prior to his entrepreneurial endeavors, Uri ran clinical and translational programs at Schering-Plough, Roche, and Gilead Sciences.

Uri holds a bachelor’s degree cum laude in biology from Cornell University. He obtained his MD from the University of Medicine and Dentistry of NJ – NJ Medical School; completed his internal medicine training at the University of Washington and New York University Medical Center; and his board certification in Infectious Diseases at the National Institutes of Health where his research focus was on viral mucosal immunology.

Biography

Dr. Lu is the Eugene and Gloria Bauer Professor of Dermatology at Northwestern University Feinberg School of Medicine in Chicago, USA. He is a physician-scientist with expertise in tissue injury and regeneration, inflammation, and wound repair. Dr. Lu serves as the Director of the NIH-funded CounterACT Center of Excellence at Northwestern. His team investigates immunomodulating treatments and conducts bench-to-bedside clinical studies to mitigate inflammation caused by sunburns, chemical skin burns from chemotherapy treatments, cutaneous lymphoma, and radiation dermatitis. His research focuses on better understanding the immune-mediated mechanisms of tissue damage caused by environmental factors. This work has led to the development of vitamin D3 as a novel intervention for promoting tissue repair and includes studies on immune modulators, drug repurposing, and nanotechnology-based solutions such as synthetic melanin.
Recent exciting discoveries include the development of topical synthetic ‘super’ melanins for skin repair, which led to his startup. Dr. Lu is the co-founder and Chief Executive Officer of Melanyze, Inc., an early-stage biotechnology company focused on developing synthetic melanin-based nanoparticles for skin regeneration, repair, and the treatment of complex inflammatory skin conditions. Melanyze is pioneering a new class of therapeutics to address critical unmet needs in dermatology and supportive oncology.

Biography

Jon Meneese is a seasoned marketing and sales executive with over 20 years of experience leading U.S. and global teams at Galderma, Alcon, and Syneos Health. Jon has overseen the development of multiple products in the Dermatology and Vision Care space and has led cross functional teams to 50+ launches in more than 30 countries around the world.

Biography

Mr. Meyers is Vice Chairman, Head of M&A and Strategic Advisory Services at H.C. Wainwright & Co. Mr. Meyers primary advisory activities encompass, M&A, licensing, credit and royalty monetizations. He has ~ 30 years of investment banking, venture capital, public health, asset management and operating experience in healthcare, with an emphasis on the life sciences. Over the course of his career, Mr. Meyers has advised on ~ $150 billion of strategic and financial transactions.
Previously, Mr. Meyers was Head of Investment Banking with T.R. Winston & Company; CEO and CIO of Arcoda Capital Management, that he founded with Scott Gottlieb, M.D.; a Partner and Portfolio Manager with two asset managers; Managing Director, Partner and Member of the Board of Global Biomedical Partners AG, a life sciences venture capital firm; Director and Relationship Manager of healthcare investment banking with Merrill Lynch & Co. Mr. Meyers was also a Vice President of Health Care Investment Banking with Cowen & Company, and a Research Associate with Hambrecht & Quist.
Mr. Meyers holds an M.P.H. in Health Policy and Management from Columbia University, and an A.B. in Biology from Brandeis University.

Biography

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the creation, early sourcing, financing and development of more than 150 companies, including 47 which have reached valuations exceeding $1 billion.
Mr. Nelsen is focused on disruptive technologies or business models and partnering with founding management teams and entrepreneurs to execute on these visions by advancing novel platform technologies with the overarching goal of improving health care and outcomes.
Some of his notable early-stage investments include Illumina (ILMN), Alnylam Pharmaceuticals (ALNY), Juno Therapeutics (JUNO – acquired by Celgene), Beam Therapeutics (BEAM), Karuna Therapeutics (KRTX – acquired by Bristol-Myers Squibb), Altos Labs, National Resilience, Xaira Therapeutics, Prime Medicine (PRME), Lyell Immunopharma (LYEL), Array BioPharma (ARRY – acquired by Pfizer), Hua Medicine (2552:HK), Vir Biotechnology (VIR), Rapport Therapeutics (RAPP), Insitro, Agios Pharmaceuticals (AGIO), Sage Therapeutics (SAGE), GRAIL (acquired by Illumina), Gossamer Bio (GOSS), Ikaria (acquired by Mallinckrodt), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), Receptos (RCPT – acquired by Celgene), Aviron (AVIR – acquired by MedImmune), Denali Therapeutics (DNLI), Syros Pharmaceuticals (SYRS), Sana Biotechnology (SANA), Verve Therapeutics (VERV), Brii Biosciences (2137:HK), Bluebird Bio (BLUE), R2 Technology (acquired by Hologic), Caliper Life Sciences (CALP – acquired by PerkinElmer), Impinj, Inc. (PI), Trubion Pharmaceuticals (TRBN – acquired by Emergent Biosolutions), Adolor (ADLR – acquired by Cubist Pharmaceuticals), deCODE Genetics (DCGN – acquired by Amgen), Editas (EDIT), 10x Genomics, Semma Therapeutics (acquired by Vertex Pharmaceuticals), Element Genomics, and IDUN Pharmaceuticals (acquired by Pfizer).
Mr. Nelsen is a director of VIR, SANA, LYEL, PRME, National Resilience, Insitro, Xaira, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute of Systems Biology, and was a director of the National Venture Capital association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.

Biography

Marco Quarta, PhD, is Co-Founder of Rubedo Life Sciences. He currently holds the CSO. Prior to that he held the CEO role for the first 6 years. Under his tenure the company raised over $60M, built its AI-driven discovery platform Alembic and moved to clinical stage-ready its first therapeutic program in dermatological chronic inflammatory diseases and skin aging.

He received his doctorate degree in Biotechnology from the University of Bologna and a Ph.D. in Neuroscience from the University of Padua. He completed a post-doc in Aging and Stem cell Biology in the lab of Prof. Thomas Rando at Stanford University. He continued his work at Stanford directing a research team at the Center for Tissue Regeneration, Repair, and Restoration at the VA Hospital in Palo Alto, CA and Stanford School of Medicine where, he established a translational program in regenerative medicine. He has over 40 publications and patents in the field of aging, stem cells, regenerative medicine, and rejuvenation.

Marco also co-founded Wetware Concepts, YEBN, and Turn Biotechnology and served as an executive board member of the European Federation of Biotechnologies. He currently sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly Bridge program, and the advisory board at the Center for Healthcare Innovation. Marco is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University. He is co-founder and President of the scientific society Phaedon Institute, a non profit focused on Longevity Medicine.

Biography

Mr. Rossi is Global Topic Leader in BCG’s Medical Aesthetics and a core member of the Health Care practice with a focus on Corporate Strategy and Marketing & Sales themes. He has over 15 years of experience in growth strategy, portfolio analysis, commercial models, GTM, pricing, loyalty programs, and digital. Mr. Rossi has led over 40 projects for multiple medical aesthetics / skincare / beauty / breast implants companies.

Prior to joining BCG, Mr. Rossi worked at Pfizer Ltd. for several years as a brand manager and, previously, as a business analyst in the strategy practice of Accenture. He holds an MBA from SDA Bocconi School of Management and a M.Sc. in Aerospace Engineering from Politecnico di Torino/Princeton University.

Biography

Dr. Nicholas Reder is a board certified and award winning pathologist and the CEO and founder of Alpenglow Biosciences, Inc., a 3D spatial biology company. He received a B.S. in biochemistry from the University of Michigan, an M.P.H. in epidemiology from Emory University, and an M.D. from Loyola University Chicago before receiving his pathology training at University of Washington, where he completed an anatomic pathology residency followed by a genitourinary pathology fellowship. While in residency, Dr. Reder won the Castleman Award, the highest honor for a pathologist under the age of 40. Dr. Reder has published more than 30 peer-reviewed journal articles and is a listed inventor on 5 patents (3 issued, 2 pending). Under his leadership, Alpenglow Biosciences has raised over a combined $35M in venture funding and grant awards. Alpenglow has created a complete end-to-end solution including the 3D imager, 3D processing, and 3D analysis to provide deep insights into therapeutic efficacy, mechanism of action, and toxicity for biopharma research and clinical trials applications.

Biography

Dr. Michael Ringel has been at BCG 25 years and is currently Managing Director and Senior Partner. He is on the Board of Hevolution US, the charitable organization focused on extending healthy aging for the benefit of all humanity, the Board of AFAR, one of the oldest organizations supporting healthy aging through biomedical research, and on the Executive Board of the Sheba Longevity Center, a clinic at one of the world's best hospitals devoted to healthy aging. Dr. Ringel holds a B.A. summa cum laude in biology from Princeton, a Ph.D. in biology from Imperial College, and a J.D. cum laude from Harvard Law School.

Biography

Mr. Sahaf is the VP of Business Development at Clexio Biosciences, where he leads partnering efforts for the company’s diverse pipeline. Prior to joining Clexio, Lior spent 3.5 years at Genentech-Roche, where he led business development deals. He holds an MBA from the University of Chicago Booth School of Business.

Biography

Cody is a bioengineer and entrepreneur that has spent all of his career bringing new health technologies to physicians and patients. Prior to joining Dr. Maurice Ferre to build DermaSensor in 2016, Cody led commercial efforts for a Silicon Valley medical device screening startup and held BD and commercial strategy roles at Genentech. His academic and research background is in business, economics and bioengineering at Brown and Stanford Universities.

Biography

Marta currently serves as Vice President of Corporate Development and Strategy at Almirall. She has more than 20 years’ experience in M&A in Pharma Industry and Investment Banking. She has a strong background in corporate development and strategy, with extensive experience in mergers and acquisitions, strategic alliances and integration. Marta started her career in Investment Banking at DC Advisory before joining Almirall where she has held several roles in Finance, Commercial and Strategy areas. She is responsible for defining and executing the M&A strategy contributing to Almirall inorganic growth in medical dermatology. She is also responsible of managing Strategic Alliances, highlighting the Biologics for which we hold European rights (with Lilly on lebrikizumab, an anti-IL13 monoclonal antibody for atopic dermatitis, and with Sun Pharma on tildrakizumab, an anti-IL23 monoclonal antibody for psoriasis).

Marta holds a Bachelors in Business Administration and MBA (ESADE, The University of Chicago Booth School of Business).

Biography

Prof. Thyssen has been with the University of Copenhagen working as a clinical dermatologist for almost 20 years. His research has examined the origins of inflammatory skin diseases, their comorbidities and disease trajectories, as well as trialed new promising treatments in AD and CHE. He has been a research fellow/guest professor at Harvard Medical School, Boston, the University of California, San Francisco and University Spital Zürich in Switzerland. Dr. Thyssen has received prestigious prizes and awards for his research, and published >700 articles in international peer reviewed journals. He has been a frequent speaker at international meetings, an industry advisor, and given testimony to regulatory authorities on several medications. In his current role as CSO in LEO Pharma, he is spear heading innovation in the company.

Biography

Dr. Edwin Tucker has over 30 years of clinical experience leading novel drug development. He is Chief Medical Officer at Jasper Therapeutics driving clinical development in mast cell mediated diseases including urticaria and asthma. Previously, he was Chief Medical Officer at Goldfinch Bio, a nephrology development stage company. Previously, he served as Chief Medical Officer at Mirum Pharmaceuticals, where he contributed to the achievement of key milestones in the development of medicines for adult and pediatric cholestatic liver disease including the first FDA approval for Alagille Syndrome. Prior to joining Mirum, Dr. Tucker was at Acerta Pharma LLC, now part of the AstraZeneca family of companies, ultimately serving as Chief Operating Officer. Prior to joining Acerta, he held leadership positions in development, medical safety and medical affairs at Genentech, Janssen Research and Development and Bayer HealthCare Pharmaceuticals.
Dr. Tucker is a member of the Royal College of Physicians (UK) and received his M.B.A. from the University of Connecticut. Dr. Tucker holds degrees in Pharmacology and Medicine from the University of Leeds, United Kingdom. Additionally, he served as a managing director at Golden Seeds, an investment firm dedicated to pursuing early-stage investment opportunities in women-led businesses.

Biography

Dr. Yu is Founder and CEO of Nuoli Health, a biotech startup making it easier, faster and cheaper to discover and develop new drugs. They are making the entire discovery and validation process easier for scientists and clinicians and connecting leads to CROs, pharmaceutical and investors, using AI to create agents and drug design guidance. They are focused on age-related conditions including Parkinson’s disease and dementia, sarcopenia and diabetic neuropathy through early partnerships.
Over the past 10 years, Ben has led AI-driven innovations and software development at notable health tech startups, Spectator Health (senior care), and Humetrix (international health communication), and Interpreta (payer analytics startup), the latter of which was acquired by Centene). Ben is a board-certified dermatologist and former faculty member at UC San Diego, with over two decades of experience spanning stem cell biology, genomics, and informatics with research funding from NIH, CIRM, Dermatology Foundation, American Skin Association and the Gate Foundation. He holds an MD and PhD, with expertise in immunology and molecular oncology.

Biography

Dr. Beddingfield is a physician-scientist and biotech entrepreneur. He is currently CEO and Board Director of Rubedo Life Sciences. He also serves as Chairman of the Board of Sagesse Bio and as a director of Cytrellis Biosystems. Previously he was an Executive Partner at Apollo Health Ventures, a longevity and age-related disease fund. He served as CEO and director of Kira Pharmaceuticals developing biologics for immunology, inflammation, and rare diseases from 2020 to 2023. He was founder, president, chief executive and member of the board of directors of Sienna Biopharmaceuticals Inc. and took the company public in 2017. Previously he served as Chief Medical Officer of Kythera Biopharmaceuticals, acquired by Allergan in 2015. He has led the development and approvals of global leading brands in medical dermatology, aesthetics, neurology, metabolic, and other therapeutic areas. These brands include Botox, Juvederm, Voluma, Kybella, Latisse, Aczone, and Tazorac.

Since completing his training, Frederick has maintained a clinical and teaching practice at UCLA. He is a board-certified dermatologist and emergency medicine physician and fellowship trained in dermatologic surgery and cutaneous oncology. Frederick completed his medical degree with honors at UNC Chapel Hill, his residency and fellowship training at UCLA, and his PhD in Policy Analysis Research at RAND. He serves on the medical advisory board of the Children’s Skin Disease Foundation and Camp Wonder. He is co-founder of the Dermatology Summit and Dermatology Innovation Forum conferences, and a Board Trustee of Advancing Innovation in Dermatology.

Biography

William Ju, MD, FAAD is a board-certified dermatologist and has over 20 years of biopharmaceutical experience in a wide variety of therapeutic areas, including dermatology. He is president and a co-founding trustee of Advancing Innovation in Dermatology, Inc. Dr. Ju has been president and chief executive officer of Follica, Inc. and chief operating officer at PTC Therapeutics, Inc. (PTCT). In addition, he has held executive positions at Pharmacia Corporation/Pfizer, Inc. Merck & Co., Inc., and Hoffmann La Roche, Inc. in a broad range of product development and leadership functions. Dr. Ju served as project leader for SUTENT®, introduced CANCIDAS® into humans, and was part of the product development teams for CRIXIVAN® and TRANSLARNA™.

Dr. Ju began his pharmaceutical career at Hoffmann-La Roche where he was a clinical leader for the development of dermatology compounds. Before entering industry, Dr. Ju was a senior staff fellow in basic research in the Laboratory of Cellular Oncology under Douglas Lowy, M.D. and was affiliated with the Dermatology Branch at the National Cancer Institute, National Institutes of Health. He obtained his M.D. with Alpha Omega Alpha honors at the University of Pennsylvania School of Medicine and his A.B. with Phi Beta Kappa honors at Princeton University.

Biography

Seth Orlow, MD, PhD has over 25 years of experience in medicine, science, and finance. As a faculty member at New York University, Dr. Orlow rose to become Chair of its leading dermatology department. He serves as a Senior Advisor with Pharus Advisors, focused on strategic transactional/investment banking advisory services in the dermatology and personal care sectors. In 1995 he co-founded Anaderm, a dermatologic discovery company backed by Pfizer and OSI Pharmaceuticals. He participated in the sale of Anaderm to Pfizer in 2002. From 2001-2010, he rose from Advisor to Partner with Easton Capital Partners, a venture capital firm focused on healthcare and consumer products. At Easton, he was involved in the sourcing, diligence, funding, oversight and exit of investments in many healthcare companies such as Acorda, Conor Medsystems, Protez, Salmedix and Transave. Dr. Orlow has licensed technologies to companies ranging from Pfizer to SkinMedica. An author of over 200 medical/scientific publications, he is an internationally sought-after speaker and thought leader. A graduate of Harvard in Biochemical Sciences and with an MD-PhD in Molecular Pharmacology from Albert Einstein College of Medicine, Dr. Orlow trained in Pediatrics and Dermatology at Mt. Sinai and Yale.

Biography

Kristen B. Slaoui, PhD has been the Chief Corporate Development Officer at Galderma, the world’s largest independent global dermatology company, since 2020. Since joining Galderma, she oversaw several significant transactions including the acquisition of Alastin Skincare in 2021, adding to Galderma’s premium portfolio. Prior to this role, she spent 20 years with GSK, first in the research labs, where her work in pulmonary disease resulted in the discovery of the long-acting muscarinic receptor antagonist in the approved medicines Anoro™ Ellipta™, Incruse™ Ellipta™, and Trelegy™ Ellipta™. She holds multiple patents, has authored more than 40 original peer-reviewed publications, and she has had ongoing roles as a peer reviewer for a dozen established medical journals. She joined GSK’s Business Development team in 2006 and held various roles of increasing seniority, and executed more than $30 billion worth of deals and acquisitions, including the $3.6 billion acquisition of Stiefel Laboratories in 2009 (where she subsequently served as VP and Head of Business Development & Licensing), participating in the $20+ billion three-part transaction with Novartis in 2015, and the $5.1 bn acquisition of Tesaro in 2018, with transactions covering the pharma R&D, commercial, emerging markets, specialty pharma and consumer spaces.

Dr. Slaoui earned Bachelor’s degrees in both Biology and Classical Studies from Gettysburg College. She earned her PhD in Physiology from The Johns Hopkins Bloomberg School of Public Health, and completed an NIH Post-Doctoral Fellowship at the University of Washington in Seattle, WA.

Biography

Qing Yu Christina Weng is a physician-scientist, entrepreneur, and biotech executive. She is the Chief Medical Officer of Pelage Pharmaceuticals, a biotech developing innovative treatments for hair loss by targeting stem cell metabolism. Prior to Pelage, Christina led business development and strategy at Kira Pharmaceuticals, a global company developing complement therapeutics. Christina co-founded Mymiel, a high-performance clean skincare line, where she served as Chief Strategy Officer. As faculty at Harvard Medical School and attending dermatologist at the Massachusetts General Hospital, she specializes in melanoma and pigmentary disorders. She is on the Board of Directors for the Dermatology Innovation Forum and the Dermatology Summit. She is on the Advisory Board for Immunis, a regenerative medicine company developing secretomes for age-related dysfunction.

Christina attended the California Institute of Technology, where she received her bachelor's degrees in Biology and English with honors. She graduated Magna Cum Laude from Harvard Medical School, where she received her medical degree and was a fellow of the Howard Hughes Medical Institute. She completed dermatology residency at the Harvard Combined Dermatology Residency Training Program with advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral bench research was at the Cutaneous Biology Research Center of MGH. Her clinical research has led to new guidelines recommended by the American Academy of Dermatology for drug monitoring. She has received research grants and awards from the Howard Hughes Medical Institute, American Skin Association, American Dermatological Association, and National Institutes of Health. She holds multiple patents.